These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

380 related items for PubMed ID: 27489350

  • 1. Phosphatidyl inositol-3 kinase (PIK3CA) E545K mutation confers cisplatin resistance and a migratory phenotype in cervical cancer cells.
    Arjumand W, Merry CD, Wang C, Saba E, McIntyre JB, Fang S, Kornaga E, Ghatage P, Doll CM, Lees-Miller SP.
    Oncotarget; 2016 Dec 13; 7(50):82424-82439. PubMed ID: 27489350
    [Abstract] [Full Text] [Related]

  • 2. Subcellular localization of FOXO3a as a potential biomarker of response to combined treatment with inhibitors of PI3K and autophagy in PIK3CA-mutant cancer cells.
    Kim HJ, Lee SY, Kim CY, Kim YH, Ju W, Kim SC.
    Oncotarget; 2017 Jan 24; 8(4):6608-6622. PubMed ID: 28036259
    [Abstract] [Full Text] [Related]

  • 3. PAK4 confers the malignance of cervical cancers and contributes to the cisplatin-resistance in cervical cancer cells via PI3K/AKT pathway.
    Shu XR, Wu J, Sun H, Chi LQ, Wang JH.
    Diagn Pathol; 2015 Sep 28; 10():177. PubMed ID: 26411419
    [Abstract] [Full Text] [Related]

  • 4. The PIK3CA E542K and E545K mutations promote glycolysis and proliferation via induction of the β-catenin/SIRT3 signaling pathway in cervical cancer.
    Jiang W, He T, Liu S, Zheng Y, Xiang L, Pei X, Wang Z, Yang H.
    J Hematol Oncol; 2018 Dec 14; 11(1):139. PubMed ID: 30547809
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. PIK3CA mutation sensitizes breast cancer cells to synergistic therapy of PI3K inhibition and AMPK activation.
    Liu S, Tang Y, Yan M, Jiang W.
    Invest New Drugs; 2018 Oct 14; 36(5):763-772. PubMed ID: 29504069
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer.
    Yang W, Hosford SR, Dillon LM, Shee K, Liu SC, Bean JR, Salphati L, Pang J, Zhang X, Nannini MA, Demidenko E, Bates D, Lewis LD, Marotti JD, Eastman AR, Miller TW.
    Clin Cancer Res; 2016 May 01; 22(9):2250-60. PubMed ID: 26733612
    [Abstract] [Full Text] [Related]

  • 12. PIK3CA mutation and CNV status and post-chemoradiotherapy survival in patients with cervical cancer.
    Martell K, McIntyre JB, Kornaga EN, Chan AMY, Phan T, Köbel M, Enwere EK, Dean ML, Ghatage P, Lees-Miller SP, Doll CM.
    Gynecol Oncol; 2020 Sep 01; 158(3):776-784. PubMed ID: 32653099
    [Abstract] [Full Text] [Related]

  • 13. A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.
    Wang L, Šuštić T, Leite de Oliveira R, Lieftink C, Halonen P, van de Ven M, Beijersbergen RL, van den Heuvel MM, Bernards R, van der Heijden MS.
    Eur Urol; 2017 Jun 01; 71(6):858-862. PubMed ID: 28108151
    [Abstract] [Full Text] [Related]

  • 14. miR‑519d‑3p/HIF‑2α axis increases the chemosensitivity of human cervical cancer cells to cisplatin via inactivation of PI3K/AKT signaling.
    Jiang L, Shi S, Li F, Shi Q, Zhong T, Zhang H, Xia Y.
    Mol Med Rep; 2021 May 01; 23(5):. PubMed ID: 33760204
    [Abstract] [Full Text] [Related]

  • 15. The E545K mutation of PIK3CA promotes gallbladder carcinoma progression through enhanced binding to EGFR.
    Zhao S, Cao Y, Liu SB, Wang XA, Bao RF, Shu YJ, Hu YP, Zhang YJ, Jiang L, Zhang F, Liang HB, Li HF, Ma Q, Xu Y, Wang Z, Zhang YC, Chen L, Zhou J, Liu YB.
    J Exp Clin Cancer Res; 2016 Jun 18; 35(1):97. PubMed ID: 27317099
    [Abstract] [Full Text] [Related]

  • 16. The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer.
    Zeng SX, Zhu Y, Ma AH, Yu W, Zhang H, Lin TY, Shi W, Tepper CG, Henderson PT, Airhart S, Guo JM, Xu CL, deVere White RW, Pan CX.
    Clin Cancer Res; 2017 Nov 01; 23(21):6580-6591. PubMed ID: 28808038
    [Abstract] [Full Text] [Related]

  • 17. PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system.
    Beaver JA, Gustin JP, Yi KH, Rajpurohit A, Thomas M, Gilbert SF, Rosen DM, Ho Park B, Lauring J.
    Clin Cancer Res; 2013 Oct 01; 19(19):5413-22. PubMed ID: 23888070
    [Abstract] [Full Text] [Related]

  • 18. CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.
    Vora SR, Juric D, Kim N, Mino-Kenudson M, Huynh T, Costa C, Lockerman EL, Pollack SF, Liu M, Li X, Lehar J, Wiesmann M, Wartmann M, Chen Y, Cao ZA, Pinzon-Ortiz M, Kim S, Schlegel R, Huang A, Engelman JA.
    Cancer Cell; 2014 Jul 14; 26(1):136-49. PubMed ID: 25002028
    [Abstract] [Full Text] [Related]

  • 19. Licochalcone A induces autophagy through PI3K/Akt/mTOR inactivation and autophagy suppression enhances Licochalcone A-induced apoptosis of human cervical cancer cells.
    Tsai JP, Lee CH, Ying TH, Lin CL, Lin CL, Hsueh JT, Hsieh YH.
    Oncotarget; 2015 Oct 06; 6(30):28851-66. PubMed ID: 26311737
    [Abstract] [Full Text] [Related]

  • 20. The role of mTOR during cisplatin treatment in an in vitro and ex vivo model of cervical cancer.
    Leisching GR, Loos B, Botha MH, Engelbrecht AM.
    Toxicology; 2015 Sep 01; 335():72-8. PubMed ID: 26201060
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.